1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Invitation to SynAct Pharma’s Capital Markets Day

SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day on Monday, September 23, 10:00-13:00 CEST at GT30, Grev Turegatan 30 in Stockholm.

The presentations will give an update on SynAct Pharma’s strategy and offer an opportunity for participants to learn more about resomelagon’s role in resolving inflammation through selective activation of the melanocortin system and the company’s next clinical development of resomelagon with the Phase IIb clinical study ADVANCE in the US and Europe.

Agenda

10:00 Introduction and corporate update – Jeppe Øvlesen, CEO
10:15 SynAct strategy and direction – Anders Kronborg, Chairman of the Board
10:25 Resolution therapy - Novel approach to the clinical management of inflammatory diseases – Prof. Mauro Perretti
10:45 Current and Future Treatments of Early Rheumatoid Arthritis and the Medical Need – Asger Reinstrup Bihlet, CSO at Sanos Group
11:05 Q&A session
11:25 Break
11:40 Resomelagon program and ADVANCE study – Thomas Jonassen, CSO
12:05 Emerging Clinical profile in newly-diagnosed RA patients - the business case – Jim Knight, CBO
12:30 Sector and market overview – Sten Scheibye, Member of the Board
12:40 Q&A session
12:55 Wrap-up and summary – Jeppe Øvlesen, CEO
13:00 Reception and lunch

Location: Grev Turegatan 30, 114 38 Stockholm
Date: Monday, September 23, 2024
Time: 10:00-13:00. The venue opens at 09:30.

The Capital Markets Day will be held in English. Presentation material will be available on SynAct’s website afterwards.

Registration for the Capital Markets Day is made by emailing investor.relations@synactpharma.com

The last day to register is September 19, 2024.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com. 

Attachments
Invitation to SynAct Pharma’s Capital Markets Day

Datum 2024-09-10, kl 15:27
Källa MFN
Bifogade filer
Invitation to SynAct Pharma’s Capital Markets Day
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!